Moderna's mRNA Flu Vaccine Demonstrates Superior Efficacy in Pivotal Trial
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna's mRNA-based seasonal flu vaccine (mRNA-1010) significantly outperformed a standard flu shot from GSK in a late-stage international trial involving over 40,000 adults, demonstrating 26.6% greater efficacy. This positive trial data arrives ahead of the previously announced August 5 PDUFA date for mRNA-1010, providing strong support for its regulatory approval. The FDA had initially rejected the application but accepted an amended one, contingent on a post-approval study in older adults. This superior efficacy in a pivotal trial substantially de-risks the approval and commercialization prospects for mRNA-1010, positioning it as a potentially market-leading product in the large seasonal flu vaccine market. This is a significant positive catalyst for Moderna, especially following recent Q1 net losses. Investors will now closely monitor the FDA's decision by the August 5 PDUFA date and the progress of regulatory reviews in other key markets like the EU, Canada, and Australia.
At the time of this announcement, MRNA was trading at $48.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.4B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.